Tania practices as both a patent attorney and solicitor, specialising exclusively in biotechnology. To this practice she brings the experience obtained in pursuing molecular and cellular immunological research to the post-doctoral level.

As an patent attorney, Tania has been involved in a range of intellectual property matters including the drafting and prosecution of biotechnology patent applications (in particular all aspects of molecular, cellular, genomic and nanotechnologies as they relate to human and non-human animals, microorganisms and plants), the provision of patentability and infringement opinions and the provision of strategic advice relating to the development and maintenance of biotech IP portfolios. She currently handles a large and diverse portfolio of matters relating to, for example:

- immunological therapies designed to modulate very specific aspects of the immunological response at either the specific or non-specific immune response level and extending to inducing either an effector response or a tolerogenic state;

- modulation of various aspects of the inflammatory cascade

- newly indentified T and B cell epitopes ad their applications (particularly in the context of modulating tolerance, T and B cell education and allergy treatment)

- tissue generation;

- bioreactor design;

- novel expression vectors, such as improved bicistronic vectors;

- stem cell therapy;

- stem cell isolation, maintenance, culture and directed differentiation;

- molecular, cellular and protein based diagnostics including gene profiling;

- in vivo based diagnostic techniques for application in oncology;

- the identification and regulation of oncogene functionality;

- new oncology therapeutic regimes designed to replace current chemotherapy methods;

- modulation of intracellular signalling pathways.

As a solicitor, Tania has practiced predominantly as a litigator where she has acted in major biotech related litigation, in particular, the erythropoietin litigation which was pursued worldwide between Genetics Institute and Kirin Angen. Davies Collison Cave acted for Genetics Institute.

Tania commenced with Davies Collison Cave in 1994 and became a partner of both the Davies Collison Cave law firm and the patent and trade mark firm in 2003.

Tania is extensively involved in the preparation and presentation of seminars, in respect of a wide variety of patent issues, to academic institutions (at both the undergraduate and postgraduate levels), research institutes and commercial organisations. She currently runs, together with Professor Sam Ricketson, the Patent Law subject of the University of Melbourne's Law School Graduate Program and she lectures on biotech related patent issues for the Patent Law subject of the Monash University Law School Graduate Program. As mentioned earlier, she developed and presented the General Immunology subject of the Monash University Post-Graduate Diploma of Immunology, which ran for 6 years as well as the Intellectual Property subject of the Monash University Graduate Diploma in the Biotechnologies of Life. Her involvement in this latter course was by invitation from Professor Alan Trounson.

Tania was also appointed by the Federal Government to sit on one of the two panels established to advise the government on the setting of terms of reference and selection process for the establishment of a biotech centre for excellence, this ultimately being awarded to the Australian Stell Cell Centre. She is currently the Institute of Patent and Trade Mark Attorney's representative for the Senate enquiry into gene patents.